Total Payments
$20,377
2024 Payments
$391.26
Companies
69
Transactions
521
Medicare Patients
8,530
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$8,551 (42.0%)
Other$7,150 (35.1%)
Travel$2,420 (11.9%)
Consulting$2,000 (9.8%)
Education$256.24 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,551 | 499 | 42.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,000 | 2 | 34.4% |
| Travel and Lodging | $2,420 | 10 | 11.9% |
| Consulting Fee | $2,000 | 1 | 9.8% |
| Education | $256.24 | 8 | 1.3% |
| Honoraria | $150.00 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Millennium Pharmaceuticals, Inc. | $6,862 | 7 | $0 (2017) |
| Heron Therapeutics, Inc. | $2,817 | 4 | $0 (2018) |
| Seattle Genetics, Inc. | $2,103 | 8 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,070 | 62 | $0 (2024) |
| Janssen Biotech, Inc. | $737.42 | 52 | $0 (2022) |
| Amgen Inc. | $662.20 | 35 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $573.23 | 44 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $571.16 | 32 | $0 (2024) |
| Merck Sharp & Dohme LLC | $462.67 | 30 | $0 (2024) |
| EISAI INC. | $460.39 | 16 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $391.26 | 15 | Myriad Genetic Laboratories, Inc. ($109.73) |
| 2023 | $262.78 | 15 | Novartis Pharmaceuticals Corporation ($52.07) |
| 2022 | $987.85 | 58 | Novartis Pharmaceuticals Corporation ($249.91) |
| 2021 | $1,205 | 59 | Eisai Inc. ($188.77) |
| 2020 | $1,180 | 72 | Amgen Inc. ($164.38) |
| 2019 | $4,283 | 144 | Seattle Genetics, Inc. ($2,103) |
| 2018 | $4,029 | 74 | Heron Therapeutics, Inc. ($2,817) |
| 2017 | $8,038 | 84 | Millennium Pharmaceuticals, Inc. ($6,862) |
All Payment Transactions
521 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $21.79 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/18/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: Oncology | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $34.13 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $109.73 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $30.00 | General |
| Category: Rare Disease | ||||||
| 06/27/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Oncology | ||||||
| 06/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $19.83 | General |
| Category: Oncology / Rare Diseases | ||||||
| 05/07/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: ONCOLOGY | ||||||
| 04/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Oncology | ||||||
| 01/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: Oncology | ||||||
| 12/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Oncology | ||||||
| 08/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2023 | SOBI, INC | Doptelet (Drug) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/25/2023 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Oncology | ||||||
| 06/27/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $16.65 | General |
| 06/20/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $17.34 | General |
| 06/13/2023 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $13.59 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 1,770 | 37,352 | $1.4M | $202,832 |
| 2022 | 49 | 1,842 | 31,230 | $1.3M | $222,175 |
| 2021 | 54 | 2,360 | 25,677 | $1.5M | $317,416 |
| 2020 | 57 | 2,558 | 46,408 | $2.8M | $432,207 |
Total Patients
8,530
Total Services
140,667
Medicare Billing
$1.2M
Procedure Codes
208
All Medicare Procedures & Services
208 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 176 | 452 | $166,336 | $40,922 | 24.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 8,215 | $164,300 | $19,525 | 11.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 960 | $63,840 | $17,708 | 27.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 38 | 176 | $124,432 | $16,291 | 13.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 237 | $59,250 | $14,731 | 24.9% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 11 | 31 | $85,622 | $8,421 | 9.8% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 12 | 55 | $27,500 | $6,812 | 24.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 111 | $27,417 | $6,402 | 23.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $28,815 | $6,010 | 20.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 34 | 282 | $44,274 | $5,690 | 12.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 180 | 487 | $31,168 | $4,985 | 16.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 11 | 276 | $49,680 | $4,947 | 10.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $21,270 | $4,549 | 21.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 33 | 86 | $26,918 | $3,814 | 14.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 178 | 506 | $18,216 | $3,797 | 20.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 167 | 447 | $8,940 | $3,755 | 42.0% |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | Office | 2023 | 11 | 21 | $14,700 | $3,734 | 25.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 15 | 17 | $18,139 | $2,912 | 16.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 52 | $17,888 | $2,444 | 13.7% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 24 | 130 | $7,800 | $2,200 | 28.2% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 13 | 58 | $16,762 | $2,184 | 13.0% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 36 | 103 | $10,197 | $1,846 | 18.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $8,930 | $1,770 | 19.8% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 16 | 252 | $108,612 | $1,727 | 1.6% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 19 | 10,200 | $20,400 | $1,607 | 7.9% |
About Dr. Anu Dham, MD
Dr. Anu Dham, MD is a Hematology & Oncology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255375531.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anu Dham, MD has received a total of $20,377 in payments from pharmaceutical and medical device companies, with $391.26 received in 2024. These payments were reported across 521 transactions from 69 companies. The most common payment nature is "Food and Beverage" ($8,551).
As a Medicare-enrolled provider, Dham has provided services to 8,530 Medicare beneficiaries, totaling 140,667 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 208 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location San Antonio, TX
- Active Since 06/16/2006
- Last Updated 01/28/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1255375531
Products in Payments
- NINLARO (Drug) $6,919
- SUSTOL (Drug) $2,817
- Lenvima (Drug) $423.02
- OPDIVO (Biological) $373.63
- KEYTRUDA (Biological) $347.40
- DARZALEX (Biological) $313.54
- TASIGNA (Drug) $261.87
- IMBRUVICA (Drug) $230.22
- Kyprolis (Drug) $197.90
- PROMACTA (Drug) $184.30
- TAGRISSO (Drug) $175.85
- IBRANCE (Drug) $170.69
- Soliris (Drug) $150.00
- SCEMBLIX (Drug) $141.53
- BENDEKA (Drug) $121.51
- Nplate (Biological) $119.18
- ALIMTA (Drug) $110.14
- MYRISK (Device) $109.73
- Neulasta (Biological) $108.88
- JAKAFI (Drug) $106.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Antonio
Dr. Timothy Fenske, Md, MD
Hematology & Oncology — Payments: $770,308
Hematology & Oncology $770,308
Dr. Paul Shaughnessy, M.d, M.D
Hematology & Oncology — Payments: $522,755
Hematology & Oncology $522,755
Francis Giles, M.d, M.D
Hematology & Oncology — Payments: $519,610
Hematology & Oncology $519,610
Dr. John Renshaw, M.d, M.D
Hematology & Oncology — Payments: $322,856
Hematology & Oncology $322,856
Dr. Elizabeth Bowhay-Carnes, M.d, M.D
Hematology & Oncology — Payments: $200,175
Hematology & Oncology $200,175
Dr. Marcela Mazo Canola, M.d, M.D
Hematology & Oncology — Payments: $150,233
Hematology & Oncology $150,233